VN February 2026

Vetnuus | February 2026 23 involves the use of live attenuated viruses (LAVs), which can replicate in the host, eliciting a more robust B and T cell response. Some of the most successful vaccination campaigns against viral pathogens have utilised LAVs, including smallpox 7 and Rinderpest 8, which were both eradicated, and the oral polio vaccine that is still part of the eradication strategy 9,10. However, LAVs may be prone to recombination and random mutation events that can result in reversion to virulence, increasing awareness about vaccine safety. One method that has been devised to simultaneously reduce viral virulence as well as the risk of replicationdriven recombination is codon deoptimization of the viral genome. Codon deoptimization (CD) and codon pair deoptimization (CPD) are strategies for virus attenuation built upon the concept that, while multiple codons exist for many common amino acids, these codons and codon pairs are not evenly employed. Rather, genomes show bias in the employment of some codons over the use of others in a species-specific manner. In CD and CPD, selected genomic regions can be rewritten in such a way as to swap out “preferred” codons or codon pairs for those less commonly encountered in the given genome. While the precise mechanisms of attenuation are unknown, it has been shown that synonymous codon substitutions can alter the co-translational protein folding mechanisms, which can increase degradation of these proteins in the cell 11. To date, CD/CPD have been utilised in the development of a number of LAV vaccine candidates. Vaccinia virus (VV), a DNA poxvirus—which serves as the backbone to many poxvirus vaccines—was found to be strongly attenuated in vivo by CD and to confer strong immunity to an otherwise fatal challenge of VV 12. When applied to the Zika virus, a positive-sense ssRNA virus of the Flaviviridae family, CPD viruses exhibited reduced virus replication fitness and some induced sterilising immunity in a mouse model, protecting against lethal challenge as well as vertical transmission during pregnancy 13. An engineered deoptimized respiratory syncytial virus (RSV), a negative-sense ssRNA virus of the Pneumoviridae family, resulted in minimal viral shedding when administered to African green monkeys that then produced a strong humoral and cellular immune response 14. A construct with CPD targeted only to the surface glycoprotein G and F ORFs showed reduced viral replication fitness and temperature sensitivity. However, some viral fitness was regained over several passages, along with defective helper particles 15. A 2021 paper by Chen et al. also found that a CPD RSV virus regained replication fitness under many serial passages, particularly through mutations in the phosphoprotein gene 16. A more recent RSV vaccine candidate with CPD applied to seven of the virus’s eleven ORFs demonstrated retained temperature sensitivity over many passages and strong humoral immunogenicity in hamsters and protective efficacy as measured at three days post-challenge (dpc) 17. CPD has also been utilised in other picornaviruses, such as poliovirus. In one such study, where the capsid region was CPD, highly modified viral clones exhibited lower RNA yield and specific infectivity 18. Furthermore, the authors found that reduced fitness was well-maintained over up to 25 serial passages, or about 50 viral replication cycles. In a separate study, Mueller et al. found that, for equal doses of viral particles, pathogenicity to the brain was significantly decreased in CPD infectious clones with the most replication-deficient phenotype 19. In a study of Enterovirus A71, a picornavirus that causes hand-foot-and-mouth disease, CD of the P1 region, along with a high-fidelity 3D polymerase, resulted in a genetically stable viral clone with decreased virulence and maintained antigenicity 20. Finally, work from our own lab has consistently revealed slower growth kinetics and reduced virulence in CPD and CD FMDV across several serotypes and strains. When CPD was applied to the capsid (P1) region of FMDV A12 and the resulting attenuated strain tested in vivo, mice were able to tolerate inoculation doses up to 10,000 times higher than the WT dose needed to cause disease, yielding a safety margin of at least 4 logs, while the safety margin of A12 WT virus was only a single log 21. In a study by Medina et al., where CPD was applied to the P1 region of A24 and Asia1, attenuated virulence and growth kinetics were observed in a serotype-independent manner both in mice and swine, though protection against later parental challenge was not observed in swine 22. In another study, various strains were derived where CD was applied to one or both of the P2 and/or P3 regions of the FMDV A24Cruzeiro genome, then tested for safety and efficacy in mice and swine 23. The P2-deopt and P2/P3-deopt strains were found to have reduced virulence in mice and elicited strong neutralising antibody titers in both mice and swine. While the A24-P2/P3Deopt strain was also found to have reduced virulence in swine, as was found with the CPD A12-P1Deopt, A24-P1Deopt and Asia1-P1Deopt strains 22, inoculation was found not to confer protection against later homologous challenge. In the current study, we evaluated the FMDV A24Cruzeiro with P2/ P3 CD region strain (heretofore A24P2/P3Deopt) for both safety and efficacy as an LAV vaccine candidate in dairy cattle according to WOAH requirements. We demonstrate that the margin of safety in cattle for this strain is at least 3 logs, with a prime-boost schedule of 104 pfu/animal conferring protection against later homologous challenge, while an intradermal-lingually (IDL) dose of up to 107 pfu (the highest dose tested) resulted in neither clinical disease nor viremia or shedding in safety-tested cattle. Additionally, sera from inoculated cattle displayed broadly neutralising capacity against a range of A topotypes and even the Asia1 serotype, suggesting the potential of such a vaccine during an outbreak scenario. RESULTS Safety Study We decided to pursue the use of A24-P2/P3Deopt as an LAV in cattle after observing significant attenuation during prior in vivo routine titration according to WOAH standards. To first test the safety of this candidate LAV, we inoculated cattle with A24-P2/P3 Deopt intradermal-lingually (IDL). The WOAH requires that for inactivated virus vaccine potency assays, all control animals must develop typical FMD lesions in 3 out of 4 feet within 8 days of inoculation with 10,000 median bovine infectious dose (BID50) of WT FMDV 24, equivalent to 2.36 x 104 pfu of our WT A24 strain. In the present study, none of the animals IDL inoculated with either 106 or 107 pfu of A24-P2/P3Deopt virus developed vesicular FMD lesions or fever (Fig 1). Mild, transient lymphopenia—a characteristic feature of FMD 25—was observed in three out of four control (wild-type inoculated) cattle at 2 dpi (#74, 75 and 76) and in one out of four cattle in the 107 pfu dose group at 1 dpi (#02). During FMD progression in cattle, FMDV is typically shed in abundance as early as one day after infection with the WT virus, which can lead to the rapid direct contact spread of the virus in both wild and domesticated herds of susceptible animals. In our study, following inoculation with FMDV A24 WT, we studied viral shedding (Fig 2) by analysing viral burden of nasal swabs by virus isolation, observing a peak at 104 to 107 pfu/ml and by RT-qPCR up to 108 to 109 genome copy particles (GCP)/ml. By contrast, no viral shedding was detected via either method following inoculation with either IDL dose of FMDV A24P2/P3Deopt. When we assessed viremia by virus isolation in A24WT inoculated animals, we found peak titers of about 103 to 104 pfu/ml and 105 to 107 GCP/ml when assessed by RT-qPCR. By contrast, we were unable to isolate infectious virus from the sera of cattle inoculated with either dose of FMDV A24P2/P3Deopt virus. Rather, we observed only “RNemia” ranging between 102 and 105 GCP/ml in 3 out of 8 A24-P2/ P3Deopt-inoculated animals (#61, 64 and 04), while RNemia was below the lower limit of detection for the remaining 5/8 FMDV A24-P2/ P3Deopt- inoculated animals. >>>24 Article

RkJQdWJsaXNoZXIy OTc5MDU=